Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaun G Goodman

Showing results (21-30 of 515) with videos related to

Pageof 52
Sort By:
Circulation|January 23, 2003
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatideShaun G Goodman, David Fitchett, Paul W Armstrong, et al.
Heart Asia|June 22, 2016
Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysisLavanya Ravichandran, Shaun G Goodman, Andrew T Yan, et al.
Atherosclerosis|December 4, 2003
Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular diseaseDennis L Sprecher, Shaun G Goodman, Paul Kannampuzha, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Access Denied? The Unintended Consequences of Pending Drug Pricing RulesAlan Kaplan, David J Stewart, Gerald Batist, et al.
American Heart Journal|October 8, 2005
Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome RegistriesAmit Segev, Bradley H Strauss, Mary Tan, et al.
American Heart Journal|June 20, 2012
Cardiogenic shock complicating acute coronary syndromes: insights from the Global Registry of Acute Coronary EventsHamza H Awad, Frederick A Anderson, Joel M Gore, et al.
American Heart Journal|January 31, 2006
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trialDavid H Fitchett, Anatoly Langer, Paul W Armstrong, et al.
Lancet (London, England)|February 15, 2002
Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE)Kim A Eagle, Shaun G Goodman, Alvaro Avezum, et al.
The Canadian Journal of Cardiology|April 5, 2011
Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC)Pamela M Katz, Aurora A Mendelsohn, Shaun G Goodman, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 15, 2022
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromesMohammad Alkhalil, Michał Kuzemczak, Alan Bell, et al.
Pageof 52

Showing results (21-30 of 515) with videos related to

Sort By:
Pageof 52
Circulation|January 23, 2003
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatideShaun G Goodman, David Fitchett, Paul W Armstrong, et al.
Heart Asia|June 22, 2016
Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysisLavanya Ravichandran, Shaun G Goodman, Andrew T Yan, et al.
Atherosclerosis|December 4, 2003
Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular diseaseDennis L Sprecher, Shaun G Goodman, Paul Kannampuzha, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Access Denied? The Unintended Consequences of Pending Drug Pricing RulesAlan Kaplan, David J Stewart, Gerald Batist, et al.
American Heart Journal|October 8, 2005
Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome RegistriesAmit Segev, Bradley H Strauss, Mary Tan, et al.
American Heart Journal|June 20, 2012
Cardiogenic shock complicating acute coronary syndromes: insights from the Global Registry of Acute Coronary EventsHamza H Awad, Frederick A Anderson, Joel M Gore, et al.
American Heart Journal|January 31, 2006
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trialDavid H Fitchett, Anatoly Langer, Paul W Armstrong, et al.
Lancet (London, England)|February 15, 2002
Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE)Kim A Eagle, Shaun G Goodman, Alvaro Avezum, et al.
The Canadian Journal of Cardiology|April 5, 2011
Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC)Pamela M Katz, Aurora A Mendelsohn, Shaun G Goodman, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 15, 2022
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromesMohammad Alkhalil, Michał Kuzemczak, Alan Bell, et al.
Pageof 52